Epigenica announces the launch of its EpiFinder Analysis Service, a fully managed, high-throughput platform designed to make advanced epigenomic research faster, more accessible and highly reproducible.
Aptamer Group and Alphazyme have executed a licensing agreement for a proprietary Optimer binder developed for hot-start polymerase chain reaction (PCR) applications.
PacBio has announced the publication of a new preprint from the HiFi Solves EMEA Consortium, “HiFi sequencing accurately identifies clinically relevant variants in paralogous genes.”
Aptamer Group, the developer of next-generation synthetic binders for the life sciences industry, has announced a new contract valued at up to £617,000 with a top-five pharmaceutical company.
Syngene International, a global contract research, development, and manufacturing organisation (CRDMO), announced site upgrades to accelerate drug discovery and development, helping clients bring novel therapies to market faster.
CN Bio, a provider of benchtop Organ-on-a-chip (OOC) solutions that accelerate drug discovery and development, today announced the launch of PhysioMimix Core.
Aptamer, a developer of next-gen synthetic binders for the life sciences industry, has announced a development contract with a pharmaceutical company to engineer Optimer binders as targeted radiopharmaceuticals for potential therapeutic applications.
Concept Life Sciences has announced the official opening, by Jonathan Pearce, the Labour Member of Parliament for High Peak, of its expanded integrated drug discovery facilities at its Chapel-en-le-Frith site.
